Cdks are the catalytic subunits of serine/threonine protein kinases which are involved in the progression through the cell cycle. Despite its high degree of homology to other cyclin-dependent kinases, Cdk5 is not activated by cyclins and there is no indication for a role in cell cycle regulation. The formation of a functional holoenzyme results upon interaction with activators p35, p39, p25 and p29. Cdk5 is expressed in all tissues, but its highest expression and activity is present in postmitotic neurons. Activated CDK5 is involved in several processes including neuronal migration, neurotransmitter release, neuronal plasticity, memory, learning, addiction, and apoptosis. Aberrant Cdk5 activity induced by the conversion of p35 to p25 plays a role in the pathogenesis of neurodegenerative diseases.
Human cyclin-dependent protein kinase CDK5, coexpressed in complex with p35NCK. Active protein expressed in Sf9 insect cells and purified as fusion protein by affinity chromatography. Molecular weight based on amino acid sequence 62.8/64.0 kDa (fusion proteins). Specific activity 11.000 pmol/mg x min (filter binding assay).
Size: 20 µg
Ordering information: shipped on dry ice
Product specific literature references:
Wei FY, Tomizawa K. (2007) „ Cyclin-dependent kinase 5 (Cdk5): a potential therapeutic target for the treatment of neurodegenerative diseases and diabetes mellitus." Mini Rev Med Chem. 7(10):1070-4.
Angelo M, Plattner F, Giese KP. (2006) „Cyclin-dependent kinase 5 in synaptic plasticity, learning and memory." J Neurochem. 99(2):353-70.
Pareek TK, Kulkarni AB. (2006) „Cdk5: a new player in pain signaling." Cell Cycle. 5(6):585-8.
Product Information
